On April 18, 2016 Celator Pharmaceuticals, Inc. (Nasdaq: CPXX) reported that an investigator-initiated clinical study at a university was reported as suspended on www.clinicaltrials.gov (Press release, Celator Pharmaceuticals, APR 18, 2016, View Source [SID:1234510991]). The study had previously been suspended due to institutional resource considerations at the university, unrelated to VYXEOS (CPX-351). The study is a phase 2 study of VYXEOS for the treatment of acute myeloid leukemia or higher risk myelodysplastic syndrome patients, who relapsed, or were refractory to, prior therapy with hypomethylating agents. Celator understands that the study has since been re-opened.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"To eliminate any confusion, we want to inform investors, the medical community and study participants of these circumstances," said Scott Jackson, Chief Executive Officer of Celator Pharmaceuticals.